☆ 4.6 Review

Renin-angiotensin system blockers during the COVID-19 pandemic: an update for patients with hypertension and chronic kidney disease

CLINICAL KIDNEY JOURNAL (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Medicine, Research & Experimental

Human soluble ACE2 improves the effect of remdesivir in SARS-CoV-2 infection

Vanessa Monteil et al.

Summary: The combination therapy of remdesivir with recombinant soluble ACE2 shows significant therapeutic effects against SARS-CoV-2 in both cell and kidney organoid models. By targeting two different modalities of the virus's life cycle, this approach improves therapeutic windows. The study lays the groundwork for investigating combinatorial regimens in future COVID-19 clinical trials.

EMBO MOLECULAR MEDICINE (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Association between renin-angiotensin-aldosterone system inhibitor use and COVID-19 hospitalization and death: a 1.4 million patient nationwide registry analysis

Gianluigi Savarese et al.

Summary: In a nationwide cohort study in Sweden, the use of RAASi was not associated with an increased risk of hospitalization for or death from COVID-19.

EUROPEAN JOURNAL OF HEART FAILURE (2021)

添加到收藏夹

News Item Cardiac & Cardiovascular Systems

Can ACEIs and ARBs be safely continued in COVID-19:- The Evidence is here at Last!

Uma Velupandian

HEART VIEWS (2021)

添加到收藏夹

Editorial Material Urology & Nephrology

The COVID-19 pandemic: consequences for nephrology

Annette Bruchfeld

Summary: The COVID-19 pandemic has had devastating consequences, with evidence showing that patients with kidney disease or at risk are disproportionately affected. Patients on dialysis or kidney transplant recipients are at higher risk of adverse outcomes, while patients with severe COVID-19 have an increased risk of acute kidney injury and potential long-term consequences for nephrological care.

NATURE REVIEWS NEPHROLOGY (2021)

添加到收藏夹

Article Transplantation

Chronic kidney disease is a key risk factor for severe COVID-19: a call to action by the ERA-EDTA

Alberto Ortiz et al.

Summary: Diabetes, hypertension, and cardiovascular disease have been traditionally considered risk factors for severe COVID-19, but recent studies have found that renal disease, especially dialysis, organ transplantation, and CKD, play a significant role in the mortality risk associated with COVID-19.

NEPHROLOGY DIALYSIS TRANSPLANTATION (2021)

添加到收藏夹

Article Critical Care Medicine

Continuation versus discontinuation of renin-angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial

Jordana B. Cohen et al.

Summary: The study aimed to evaluate the impact of continuing versus discontinuing renin-angiotensin system inhibitors on outcomes in patients admitted to hospital with COVID-19. Results showed that continuing these medications had no significant effects compared to discontinuation in patients with COVID-19.

LANCET RESPIRATORY MEDICINE (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Soluble ACE2-mediated cell entry of SARS-CoV-2 via interaction with proteins related to the renin-angiotensin system

Man Lung Yeung et al.

Summary: Research has identified the crucial role of human host factors and sACE2 protein in virus dependency factors, cell entry, and other aspects of SARS-CoV-2 infection, shedding light on the pathogenesis of COVID-19 and potential treatment strategies.

CELL (2021)

添加到收藏夹

Review Peripheral Vascular Disease

Renin-angiotensin system blockade in patients with chronic kidney disease: benefits, problems in everyday clinical use, and open questions for advanced renal dysfunction

Charalampos Loutradis et al.

Summary: Studies have shown significant renoprotective effects of renin-angiotensin system (RAS) blockers in chronic kidney disease (CKD) patients with high levels of albuminuria, particularly in those with more severe conditions. However, randomized trials on the initiation or maintenance of RAS blockers in patients with advanced CKD are scarce, leading to uncertainty among clinicians. Fear of hyperkalemia or acute renal decline also contributes to underprescription of RAS blockers in Stage 4 and 5 CKD patients.

JOURNAL OF HUMAN HYPERTENSION (2021)

添加到收藏夹

Review Urology & Nephrology

KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease Abstracts

[Anonymous]

KIDNEY INTERNATIONAL (2021)

添加到收藏夹

Review Urology & Nephrology

Renin-angiotensin system blockade in the COVID-19 pandemic

Jordana B. Cohen et al.

Summary: During the early months of the COVID-19 pandemic, controversy arose over the hypothesis that pharmacologic inhibitors of the renin-angiotensin system (RAS) may exacerbate COVID-19 severity. While some evidence suggests potential protective effects of ACE2 and RAS blockade on acute lung injury, there are risks associated with discontinuing these medications. Further research and examination of this topic are warranted to improve understanding of these complex relationships.

CLINICAL KIDNEY JOURNAL (2021)

添加到收藏夹

Review Medicine, General & Internal

Changes in the respiratory function of COVID-19 survivors during follow-up: A novel respiratory disorder on the rise?

Afroditi K. Boutou et al.

Summary: This review found that patients who recovered from COVID-19 present abnormal respiratory function at short-term follow-up, mainly with reduced lung diffusion and a restrictive pattern. However, more research is needed to determine the exact incidence of these abnormalities and whether they may be temporary or permanent.

INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2021)

添加到收藏夹

Review Medicine, General & Internal

Association Between Renin-Angiotensin-Aldosterone System Inhibitors and Clinical Outcomes in Patients With COVID-19 A Systematic Review and Meta-analysis

Ranu Baral et al.

Summary: A systematic review and meta-analysis found that receipt of ACEIs or ARBs was not associated with a higher risk of multivariable-adjusted mortality and severe adverse events among patients with COVID-19, especially for those with hypertension.

JAMA NETWORK OPEN (2021)

添加到收藏夹

Article Urology & Nephrology

Renin-Angiotensin System Blockers and the Risk of COVID-19-Related Mortality in Patients with Kidney Failure

Maria Jose Soler et al.

Summary: The use or discontinuation of ACEis/ARBs does not significantly affect mortality in kidney transplant recipients and dialysis patients with COVID-19. The study shows that these medications have no impact on the severity of COVID-19 in this population.

CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2021)

添加到收藏夹

Review Pharmacology & Pharmacy

An Insight on Multicentric Signaling of Angiotensin II in Cardiovascular system: A Recent Update

Kanika Verma et al.

Summary: The multifaceted nature of the renin-angiotensin system allows it to play various roles in the pathogenesis of cardiovascular diseases. Angiotensin II within the RAS family has diverse potential effects and the AT(1)R receptor is known to mediate the majority of its functions, with crosstalk between its signaling cascades and other pathways being recognized. Recent research focuses on understanding Ang II receptor signal transduction and the functional significance in the cardiovascular system for potential therapeutic applications, as well as exploring the role of stem cell-based therapies in cardiovascular health.

FRONTIERS IN PHARMACOLOGY (2021)

添加到收藏夹

Article Critical Care Medicine

Discontinuation versus continuation of renin-angiotensin-system inhibitors in COVID-19 (ACEI-COVID): a prospective, parallel group, randomised, controlled, open-label trial

Axel Bauer et al.

Summary: Stopping ACEI or ARB treatment did not significantly affect the maximum severity of COVID-19, but may result in a faster and better recovery. The decision to continue or discontinue should be made on an individual basis, considering the risk profile, indication for RAS inhibition, and availability of alternative therapies and outpatient monitoring options.

LANCET RESPIRATORY MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Telmisartan for treatment of Covid-19 patients: An open multicenter randomized clinical trial

Mariano Duarte et al.

Summary: This study in Argentina investigated the potential treatment of Covid19-induced lung inflammation using telmisartan. Results showed that patients treated with telmisartan had better CRP levels and shorter time to discharge compared to standard care alone.

ECLINICALMEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

A multi-center phase II randomized clinical trial of losartan on symptomatic outpatients with COVID-19

Michael A. Puskarich et al.

Summary: The study found that losartan did not reduce hospitalizations in low-risk outpatients with mild symptomatic COVID-19, and viral load was not affected by the treatment. This suggests that initiation of losartan treatment for this group is not supported.

ECLINICALMEDICINE (2021)

添加到收藏夹

Article Medical Informatics

Renin-angiotensin system blockers and susceptibility to COVID-19: an international, open science, cohort analysis

Daniel R. Morales et al.

Summary: The study found no significant association between the use of ACEIs or ARBs and COVID-19 diagnosis and hospital admission in patients with hypertension, suggesting that users should not stop or change their treatment to reduce the risk of COVID-19.

LANCET DIGITAL HEALTH (2021)

添加到收藏夹

Editorial Material Critical Care Medicine

Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target

Haibo Zhang et al.

INTENSIVE CARE MEDICINE (2020)

添加到收藏夹

Article Virology

Receptor recognition by novel coronavirus from Wuhan: An analysis based on decade-long structural studies of SARS

Yushun Wan et al.

JOURNAL OF VIROLOGY (2020)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

The Science Underlying COVID-19 Implications for the Cardiovascular System

Peter P. Liu et al.

CIRCULATION (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

A hypothesized role for dysregulated bradykinin signaling in COVID-19 respiratory complications

Joseph A. Roche et al.

FASEB JOURNAL (2020)

添加到收藏夹

Article Medicine, General & Internal

Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area

Safiya Richardson et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

添加到收藏夹

Article Medicine, General & Internal

Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy

Giacomo Grasselli et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

添加到收藏夹

Article Medicine, General & Internal

Features of 20133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study

Annemarie B. Docherty et al.

BMJ-BRITISH MEDICAL JOURNAL (2020)

添加到收藏夹

Article Medicine, General & Internal

Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study

Christopher M. Petrilli et al.

BMJ-BRITISH MEDICAL JOURNAL (2020)

添加到收藏夹

Article Medicine, General & Internal

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Fei Zhou et al.

LANCET (2020)

添加到收藏夹

Letter Critical Care Medicine

Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?

Lei Fang et al.

LANCET RESPIRATORY MEDICINE (2020)

添加到收藏夹

Editorial Material Urology & Nephrology

Controversies of renin-angiotensin system inhibition during the COVID-19 pandemic

Andrew M. South et al.

NATURE REVIEWS NEPHROLOGY (2020)

添加到收藏夹

Article Medicine, General & Internal

Renin-Angiotensin-Aldosterone System Blockers and the Risk of Covid-19

Giuseppe Mancia et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Medicine, General & Internal

Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Covid-19

Harmony R. Reynolds et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Peripheral Vascular Disease

Age and Multimorbidity Predict Death Among COVID-19 Patients Results of the SARS-RAS Study of the Italian Society of Hypertension

Guido Iaccarino et al.

HYPERTENSION (2020)

添加到收藏夹

Review Peripheral Vascular Disease

Hypertension and related diseases in the era of COVID-19: a report from the Japanese Society of Hypertension Task Force on COVID-19

Shigeru Shibata et al.

HYPERTENSION RESEARCH (2020)

添加到收藏夹

Review Medicine, General & Internal

ACE2 as a Therapeutic Target for COVID-19; Its Role in Infectious Processes and Regulation by Modulators of the RAAS System

Veronique Michaud et al.

JOURNAL OF CLINICAL MEDICINE (2020)

添加到收藏夹

Review Peripheral Vascular Disease

COVID-19 and hypertension-evidence and practical management: Guidance from the HOPE Asia Network

Kazuomi Kario et al.

JOURNAL OF CLINICAL HYPERTENSION (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Factors associated with COVID-19-related death using OpenSAFELY

Elizabeth J. Williamson et al.

NATURE (2020)

添加到收藏夹

Article Urology & Nephrology

Results from the ERA-EDTA Registry indicate a high mortality due to COVID-19 in dialysis patients and kidney transplant recipients across Europe

Kitty J. Jager et al.

KIDNEY INTERNATIONAL (2020)

添加到收藏夹

Article Peripheral Vascular Disease

Clinical and Proteomic Correlates of Plasma ACE2 (Angiotensin-Converting Enzyme 2) in Human Heart Failure

Julio A. Chirinos et al.

HYPERTENSION (2020)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology

Petar M. Seferovic et al.

EUROPEAN JOURNAL OF HEART FAILURE (2019)

添加到收藏夹

Review Pharmacology & Pharmacy

Novel Therapeutic Approaches Targeting the Renin-Angiotensin System and Associated Peptides in Hypertension and Heart Failure

Lauren B. Arendse et al.

PHARMACOLOGICAL REVIEWS (2019)

添加到收藏夹

Article Physiology

Classical Renin-Angiotensin System in Kidney Physiology

Matthew A. Sparks et al.

COMPREHENSIVE PHYSIOLOGY (2014)

添加到收藏夹

Article Oncology

Acute respiratory distress syndrome leads to reduced ratio of ACE/ACE2 activities and is prevented by angiotensin-(1-7) or an angiotensin II receptor antagonist

Roelie M. Woesten-van Asperen et al.

JOURNAL OF PATHOLOGY (2011)

添加到收藏夹

Article Physiology

Localization of ACE2 in the renal vasculature: amplification by angiotensin II type 1 receptor blockade using telmisartan

Maria Jose Soler et al.

AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2009)

添加到收藏夹

Article Peripheral Vascular Disease

Olmesartan is an angiotensin II receptor blocker with an inhibitory effect on angiotensin-converting enzyme

Jun Agata et al.

HYPERTENSION RESEARCH (2006)

添加到收藏夹

Article Urology & Nephrology

Effects of renin-angiotensin system blockade on renal angiotensin-(1-7) forming enzymes and receptors

CM Ferrario et al.

KIDNEY INTERNATIONAL (2005)

添加到收藏夹

Article Biochemistry & Molecular Biology

A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury

K Kuba et al.

NATURE MEDICINE (2005)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2

CM Ferrario et al.

CIRCULATION (2005)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.